2024 Drug Pricing Pharmaceutical Manufacturing 
Drug Channels
JULY 23, 2024
It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. These data remain inconvenient for drug pricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2023.
Pharmaceutical Commerce
JUNE 17, 2025
A Further Examination of Pharmacy Benefit Managers Nicholas Saraceno, Editor March 29th 2024 Podcast Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Biosimilars
AUGUST 14, 2024
Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceutical manufacturers. On July 31, 2024, CMS published a proposed rule to codify its guidances, with some changes.
Proxsys Rx
APRIL 1, 2025
billion annually because of these restrictions, as drug companies limit 340B discounts on medications purchased through contract pharmacies. billion in 340B savings is at risk, due to increasing limitations imposed by pharmaceutical manufacturers which could further strain the healthcare safety net and patient care services.
Pharmaceutical Commerce
JUNE 17, 2025
AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drug prices based on real-world patient outcomes. Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake John F.
FDA Law Blog: Biosimilars
APRIL 16, 2024
Gaulkin — On April 10, the Fourth Circuit unanimously affirmed a summary judgment ruling for the Centers for Medicare & Medicaid Services (CMS) regarding the agency’s definitions of “line-extension drug” and “new formulation” for purposes of determining rebates that drug manufacturers may owe the Medicaid Drug Rebate Program (MDRP).
Pharmaceutical Commerce
JUNE 18, 2025
How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Expert insights. Personalized for you.
52 
Let's personalize your content